Share This Page
Drugs in ATC Class R06AC
✉ Email this page to a colleague
Drugs in ATC Class: R06AC - Substituted ethylene diamines
| Tradename | Generic Name |
|---|---|
| PBZ | tripelennamine citrate |
| PBZ-SR | tripelennamine hydrochloride |
| PBZ | tripelennamine hydrochloride |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class R06AC: substituted ethylene diamines
What drugs sit in ATC R06AC (substituted ethylene diamines) and who sells them?
ATC R06AC is a small therapeutic class within antihistamines for systemic use (R06). The class name captures substituted ethylene diamines, historically associated with first-generation antihistamines in several markets.
Market reality check (commercial relevance)
- In most major jurisdictions, R06AC activity is dominated by legacy small-molecule antihistamines that are typically off-patent by the time they are listed in modern ATC groupings.
- As a result, patent activity tends to shift from primary API composition to:
- formulation/solid-state improvements,
- method-of-use (new indications, dosing regimens),
- combination products (where the class member is paired with another active),
- manufacturing/process patents.
Commercial implications
- Pricing pressure is usually driven by generic substitution and supply-chain consolidation, not by brand exclusivity.
- Patent estates that still matter in this class are more likely to be narrow and formulation- or process-scoped rather than broad composition monopolies.
No drug-level enumeration, Orange Book status, or patent expiry schedule can be produced without a specific list of R06AC member substances, their FDA/EMA registrations, and their Orange Book/EP register entries. This analysis cannot be completed accurately from the ATC category label alone.
How do patent estates typically look for substituted ethylene diamines (composition vs formulation vs method-of-use)?
Expected patent pattern in R06AC Because substituted ethylene diamines are largely mature, the remaining enforceable IP (when it exists) usually falls into one of these buckets:
-
Formulation and solid-state
- Controlled-release or extended-release variants
- Microencapsulation, granulation, or particle-size modifications
- Salt selection (where applicable), polymorphs, hydrates, solvates
- Bioavailability optimization (pH-dependent formulations, solubility enhancement)
-
Manufacturing and process
- Specific reaction conditions or purification steps for the substituted ethylene diamine core
- Scalable synthesis routes to reduce impurities or improve yield
- Sterilization and handling for specific dosage forms
-
Method-of-use
- New age cohorts, symptom-specific dosing, or combination therapy regimens
- Off-label but later formally studied indications in some jurisdictions
-
Combination product patents
- Pairing with decongestants, leukotriene modifiers, corticosteroids, or other antihistamines
- Fixed-dose combinations that can generate separate exclusivity and listing strategies
Why composition breadth is uncommon
- For first-generation antihistamines and comparable legacy chemotypes, original composition-of-matter coverage usually expires long before present-day market activity.
- Litigation, when it exists, more often turns on whether the generic infringes a formulation/process claim or a specific manufacturing method, not on whether the active ingredient itself is protected.
When does exclusivity end for substituted ethylene diamines in major markets?
Executive answer For this ATC class, exclusivity is typically determined by:
- patent term (composition/formulation/process),
- any regulatory exclusivity in the relevant jurisdiction (often limited for older single-ingredient small molecules),
- data exclusivity tied to a specific formulation or filing strategy.
Practical pattern
- Many members of R06AC are already beyond first filing-era patent terms.
- What remains, where it exists, is typically tied to:
- reformulations (new dosage forms),
- new combinations,
- line extensions.
What this means for entry risk
- Generic entry risk is usually driven by whether:
- the product is a novel formulation still within claim life, or
- the generic can use a commercially equivalent formulation that avoids patent scope (design-around).
A precise “when does it lose exclusivity” timeline cannot be produced without the specific R06AC substances (and their marketed brand/generic SKUs), and without linking to their patent numbers, filing dates, and regulatory exclusivity grants.
What patents protect substituted ethylene diamines, and what claim types show up in challenges?
Expected infringement themes Patent challenges for this class (Paragraph IV in the US context) generally cluster around:
- composition claims for modified salts or specific stereochemistry (when relevant),
- formulation claims for extended-release or controlled-release designs,
- process claims that can be avoided by alternative synthesis routes,
- method-of-use claims that are hard to assert without clear labeling carve-ins.
Claim-scope reality
- Formulation patents often require proof of infringing parameters such as:
- dissolution profile,
- excipient composition,
- particle-size distributions,
- manufacturing-defined characteristics.
- Process patents turn on:
- whether the generic uses the claimed reaction sequence or purification step,
- whether evidence exists for actual commercial manufacturing.
What is the Orange Book status of ATC R06AC substituted ethylene diamines?
Blocked by missing drug-level mapping Orange Book status is substance- and NDA/BLA-specific. ATC category mapping alone is not sufficient to identify:
- the relevant NDA numbers,
- the specific strength/dosage forms,
- listed patents,
- expiration dates and submission bases.
No accurate Orange Book table (NDA, patent number, listed use, expected expiry) can be produced from the ATC label alone.
Which companies are challenging patents for substituted ethylene diamines?
Blocked by missing substance list Generic challenge identification requires:
- the relevant Orange Book-listed patents,
- the ANDA filer(s),
- court dockets by NDA,
- case captions and filing dates.
No accurate list of challengers and case outcomes can be produced without a drug-to-patent mapping for R06AC.
How strong is the patent estate for substituted ethylene diamines?
Class-level assessment At the ATC class level, patent strength is typically:
- low on core composition-of-matter (expired for most legacy actives),
- medium to low on formulation claims unless the marketed product uses a technically specific, hard-to-design-around formulation,
- medium where combination products exist with brand-protected fixed-dose embodiments.
Investment and licensing implication
- If evaluating a deal, enforceable value in R06AC more often resides in:
- a specific modified-release technology,
- a salt/polymorph that maps cleanly to commercial product characteristics,
- a manufacturing differentiator that is difficult to replicate without using a protected process.
A quantified strength score (per-patent remaining life, claim breadth, litigation history) requires specific patent numbers and jurisdictions.
What generic entry risks exist for substituted ethylene diamines?
Entry-risk drivers
- Is the marketed product still covered by any valid listed patent claims?
- Does the generic design-around an excipient/particle-size/dissolution profile requirement?
- Is there an enforceable method-of-use claim tied to labeled dosing?
- Is there an exclusivity barrier tied to a specific formulation NDA filing?
Typical outcome in mature antihistamine classes
- If the active ingredient is off patent, entry is usually blocked only when:
- there is a still-live formulation/process patent that the generic must copy or cannot reasonably avoid.
- If no live formulation/process claims exist, ANDA or local generic entry tends to be straightforward.
Generic entry risk cannot be rated for this ATC class without knowing the exact market product(s), label status, and live patent claims.
How do substituted ethylene diamines compare with other antihistamine classes in patent posture?
High-level comparison
- Older antihistamines across ATC R06 often share the same trajectory:
- early patents on the actives expire,
- late patents on formulations remain the main differentiator.
- Classes with more modern reformulations or newer combinations can maintain higher patent leverage.
- R06AC is generally consistent with mature actives, so patent leverage is usually narrower than in newer antihistamine chemotypes.
What manufacturing/IP barriers slow down generic substitution?
Barrier types that matter
- Process patents with narrow, technically defined steps that are hard to validate or reproduce without infringement.
- Extended-release technologies where the performance relies on a specific manufacturing method that is difficult to replicate.
- Solid-state patents that tie to a specific polymorph/hydrate form used in commercial supply.
Evidence-based enforcement
- Enforcement often depends on:
- expert testing of the generic’s dissolution profile and solid-state form,
- discovery records on generic manufacturing parameters.
Key Takeaways
- ATC R06AC (substituted ethylene diamines) is typically a mature antihistamine category where current IP leverage, when present, usually sits in formulation, solid-state, process, or combination patents rather than broad composition-of-matter.
- Market dynamics are usually governed by generic competition and line extensions, not primary active ingredient exclusivity.
- A defensible patent landscape for R06AC requires drug-level mapping to NDA/EMA registrations and patent identifiers; the ATC label alone does not support accurate Orange Book status, patent expiry schedules, or litigation/Paragraph IV histories.
FAQs
- How do formulation patents for antihistamines in ATC R06AC typically get asserted in US litigation?
- What evidence is most persuasive to prove infringement of extended-release formulation patents for legacy antihistamines?
- Do solid-state patents (polymorphs/hydrates) meaningfully delay generics for substituted ethylene diamines?
- How do combination-product patents change the generic entry timeline versus single-ingredient products?
- What regulatory strategies (citations, formulation-specific ANDAs) most affect patent challenges for this class?
References
No sources cited.
More… ↓
